貨號(hào)：GS40110

Cabiralizumab is an investigational humanized monoclonal antibody designed for cancer therapy, specifically functioning as an inhibitor of the colony-stimulating factor 1 receptor (CSF-1R). It was developed with the primary goal of modulating the tumor microenvironment by targeting immunosuppressive tumor-associated macrophages (TAMs). Clinical trials explored its use, particularly in combination with checkpoint inhibitors such as nivolumab (anti-PD-1), for advanced solid tumors including pancreatic cancer, renal cell carcinoma, and non-small cell lung cancer. While early-phase studies demonstrated some potential for synergistic activity, its overall development has been limited, and the drug has not progressed to widespread regulatory approval.